Cargando…

Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series

BACKGROUND: The continuation of anti-vascular endothelial growth factor (anti-VEGF) treatment after achieving stability in patients with neovascular age-related macular degeneration has generally been advocated. In our own patients, we thought to assess whether continued anti-VEGF treatment is capab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garweg, Justus G., Traine, Peter G., Garweg, Richard A., Wons, Juliana, Gerhardt, Christin, Pfister, Isabel B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956692/ https://www.ncbi.nlm.nih.gov/pubmed/33941877 http://dx.doi.org/10.1038/s41433-021-01562-6

Ejemplares similares

Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis
por: Garweg, Justus G., et al.
Publicado: (2021)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
por: Kaya, Cagdas, et al.
Publicado: (2019)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis
por: Hänsli, Christof, et al.
Publicado: (2023)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019)

Cytokine profiles in the aqueous humor and serum of patients with dry and treated wet age-related macular degeneration
por: Spindler, Jan, et al.
Publicado: (2018)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsby’s Fundus Dystrophy: A Systematic Review
por: Baston, Arthur, et al.
Publicado: (2021)

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
por: Zirpel, Johanna J., et al.
Publicado: (2021)

Functional Outcome After Macular Hole Surgery: Comparison of Standard Perimetry with Microperimetry
por: Wons, Juliana, et al.
Publicado: (2022)

Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma
por: Garweg, Justus G., et al.
Publicado: (2017)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

Effect of Preoperative Intraocular Pressure in Patients with and without Intolerance to Their IOP-Lowering Medication on the Outcome of Trabectome Surgery
por: Wons, Juliana, et al.
Publicado: (2021)

Ocular TGF-β, Matrix Metalloproteinases, and TIMP-1 Increase with the Development and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus
por: Saucedo, Lucia, et al.
Publicado: (2021)

Risks and Challenges in Interpreting Simultaneous Analyses of Multiple Cytokines
por: Pfister, Isabel B., et al.
Publicado: (2020)

A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Gemenetzi, Maria, et al.
Publicado: (2017)

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study
por: Staurenghi, Giovanni, et al.
Publicado: (2020)

Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
por: Jaki Mekjavic, Polona, et al.
Publicado: (2018)

Association of inflammation-related markers and diabetic retinopathy severity in the aqueous humor, but not serum of type 2 diabetic patients
por: Saucedo, Lucia, et al.
Publicado: (2023)

Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review
por: Garweg, Justus G., et al.
Publicado: (2023)

Biomarkers for PVR in rhegmatogenous retinal detachment
por: Zandi, Souska, et al.
Publicado: (2019)

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen
por: Hirata, Yuki, et al.
Publicado: (2022)

Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial
por: Garweg, Justus G., et al.
Publicado: (2022)

Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment
por: Garweg, Justus G., et al.
Publicado: (2018)

Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair
por: Hänsli, Christof, et al.
Publicado: (2022)

Aqueous Humor Apolipoprotein Concentration and Severity of Diabetic Retinopathy in Type 2 Diabetes
por: Saucedo, Lucia, et al.
Publicado: (2022)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Hybrid 23/27 Gauge Vitrectomy – Combining the Charm of 27G with the Efficacy of 23G
por: Garweg, Justus G, et al.
Publicado: (2020)

Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations
por: Zandi, Souska, et al.
Publicado: (2021)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
por: Wons, Juliana, et al.
Publicado: (2017)

Impact of Vitreal Tamponade on Functional Outcomes in Vitrectomy with ILM Peeling in Primary Macula-Involving Retinal Detachment: A Retrospective Analysis
por: Deiss, Mario, et al.
Publicado: (2020)

Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
por: Mrejen, Sarah, et al.
Publicado: (2015)

Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration
por: Lee, Andy, et al.
Publicado: (2020)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Prevalence of Polypoidal Choroidal Vasculopathy in Eyes with Neovascular Age-Related Macular Degeneration Resistant to Intravitreal Anti-VEGF Treatment
por: Menteş, Jale, et al.
Publicado: (2022)

Phacoemulsification Surgery in Eyes with Neovascular Age-Related Macular Degeneration
por: Grixti, Andre, et al.
Publicado: (2014)

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan
por: Cheng, Cheng-Kuo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iti9cjo521heup1mdoeuchaqjn